Biopharma · FDA Approvals · Stock

ACRS Aclaris

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, …

Assets on file: ATI-052, modzatinib

Start live analysis of ACRS Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for ACRS, including recently decided ones.

Nothing scheduled in this window.

Recent first-hand events

Every first-hand event for ACRS, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Oct 27, 2026

10:06 AM

ACRSAclaris

Aclaris Reports Positive Phase 1b POC Results for ATI-052 in AD and Asthma; Prioritizes EoE Phase 2b

Aclaris announced positive primary analysis results from two Phase 1b proof-of-concept trials of ATI-052 showing rapid, broad efficacy in severe AD (EASI and itch improvements) and mild-to-moderate asthma (FeNO and FEV1 improvements), plus favorable safety with no conjunctivitis. The company will prioritize Phase 2b development in eosinophilic esophagitis, with initiation planned for early 2027.

Topline resultsSEC 8-K Open record

Aug 6, 2026

08:35 PM

ACRSAclaris

Aclaris: FDA grants Fast Track for modzatinib (ATI-2138) in LP

The FDA granted Fast Track designation to modzatinib for moderate to severe lichen planus, enabling more frequent FDA interactions, rolling NDA review, and potential Priority Review eligibility. Aclaris plans to start a Phase 2b trial in Q4 2026.

FDA designationCompany press release